Patents Represented by Attorney, Agent or Law Firm Cheryl H. Agris
  • Patent number: 6190905
    Abstract: An isolated and purified enzyme exhibiting protease activity at a pH of 4-7 which exhibits protease in 5% hydrogen peroxide and which is encoded by a DNA sequence which hybridizes to a DNA sequence depicted in SEQ ID NO: 1 or 2. Methods are described for using the protease compositions in reducing vescosity, cleaning contact lenses, baking, and preparing animal feed.
    Type: Grant
    Filed: September 29, 1999
    Date of Patent: February 20, 2001
    Inventors: Henrik Dalbøge, Stephan Christgau, Lene Nonboe Andersen, Lene Venke Kofod, Markus Sakari Kauppinen, Jack Bech Nielsen, Claus Dambmann
  • Patent number: 6172750
    Abstract: There is provided a method or system that utilizes fluorescence in a sample that would otherwise yield inaccurate results due to spectrally interfering components. The system quantifies spectral interference of a fluorescent label.
    Type: Grant
    Filed: September 18, 1997
    Date of Patent: January 9, 2001
    Inventor: Robert W. Brocia
  • Patent number: 6080567
    Abstract: An enzyme exhibiting xylanase activity, which enzyme is immunologically reactive with antibody raised against a purified xylanase derived from Aspergillus aculeatus, CBS 101.43. The enzyme may be used for degrading plant cell wall components, e.g., in the preparation of feed, in baking, in the paper and pulp industry, and in connection with separation of wheat into starch and gluten.
    Type: Grant
    Filed: July 16, 1998
    Date of Patent: June 27, 2000
    Assignee: Novo Nordisk A/S
    Inventors: Lene Venke Kofod, Markus Sakari Kauppinen, Stephan Christgau, Hans Peter Heldt-Hansen, Henrik Dalb.o slashed.ge, Lene Nonboe Andersen, Joan Qi Si, Tina Sejersg.ang.rd Jacobsen, Niels Munk, Anette Mullertz
  • Patent number: 6022858
    Abstract: A pharmaceutical formulation comprising a growth hormone pretreated with zinc and optionally lysine or calcium ions shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved formulation at ambient temperature.
    Type: Grant
    Filed: July 23, 1998
    Date of Patent: February 8, 2000
    Assignee: Novo Nordisk A/S
    Inventors: Hans Holmegaard S.o slashed.rensen, Ole Hvilsted Olsen, Lars Thim, Christensen Thorkild, Per Balschmidt
  • Patent number: 5998190
    Abstract: An isolated and purified enzyme exhibiting protease activity at a pH of 4-7 which exhibits protease activity in 5% hydrogen peroxide and which is encoded by a DNA sequence which hybridizes to a DNA sequence depicted in SEQ ID NO. 1 or 2.
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: December 7, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Henrik Dalb.o slashed.ge, Stephan Christgau, Lene Nonboe Andersen, Lene Venke Kofod, Markus Sakari Kauppinen, Jack Bech Nielsen, Claus Dambmann
  • Patent number: 5977069
    Abstract: A pharmaceutical preparation comprising a growth hormone and asparagine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature.
    Type: Grant
    Filed: January 28, 1992
    Date of Patent: November 2, 1999
    Assignee: Novo Nordisk A/S
    Inventor: Hans Holmegaard S.o slashed.rensen
  • Patent number: 5972042
    Abstract: Methods of dyeing a material, comprising treating the material with a dyeing system which comprises (a) one or more mono-, di- or polycyclic aromatic or heteroaromatic compounds, and (b) (i) a hydrogen peroxide source and an enzyme exhibiting peroxidase activity or (ii) an enzyme exhibiting oxidase activity on the one or more aromatic or heteroaromatic compounds; wherein the material is a fabric, yarn, fiber, garment or film made of cotton, diacetate, flax, linen, lyocel, polyacrylic, synthetic polyamide, polyester, ramie, rayon, tencel, or triacetate.
    Type: Grant
    Filed: December 19, 1996
    Date of Patent: October 26, 1999
    Assignees: Novo Nordisk A/S, Novo Nordisk Bio-Chem North America
    Inventors: Martin Barfoed, Ole Kirk
  • Patent number: 5955281
    Abstract: The invention is directed to a method for identifying substances acting as ligands for transfected receptors by using transfected markers to measure receptor/ligand interactions.
    Type: Grant
    Filed: November 7, 1997
    Date of Patent: September 21, 1999
    Assignee: Acadia Pharmaceuticals, Inc.
    Inventor: Mark Robert Brann
  • Patent number: 5919817
    Abstract: The present invention relates to therapeutically active compounds of formula I ##STR1## a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in the prevention or treatment of estrogen related diseases or syndromes.
    Type: Grant
    Filed: October 27, 1997
    Date of Patent: July 6, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Poul Jacobsen, Svend Treppendahl, Paul Stanley Bury, Anders Kanstrup, Lise Brown Christiansen
  • Patent number: 5919697
    Abstract: The invention is directed to agents used in the retention of color values on fabrics formed from cellulose fibers (color clarification agents) and to a method for treatment of such fabrics. The method comprises treating a colored fabric with a cellulase and a polymer selected from the group consisting of a polyalkylene oxide graft polymer, a polyamino acid polymer, and a carboxylated polysaccharide polymer in an amount effective to preserve the color of the fabric after at least one wash cycle.
    Type: Grant
    Filed: October 18, 1996
    Date of Patent: July 6, 1999
    Assignees: Novo Nordisk A/S, Novo Nordisk Biochem North America, Inc.
    Inventors: Sonja I. Salmon, Anita R. Mishra, Jack B. Nielsen
  • Patent number: 5919812
    Abstract: The present invention provides novel uses of compounds of general formula I ##STR1## wherein R1, R4 and R5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino)(lower alkoxy); and R2 and R3 are individually hydrogen or lower alkyl, or as a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of idiopathic or physiologic gynaecomastia.
    Type: Grant
    Filed: March 4, 1997
    Date of Patent: July 6, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Niels Korsgaard, Michael Shalmi, Birgitte Hjort Guldhammer
  • Patent number: 5912132
    Abstract: The invention is directed to a method for identifying substances acting as ligands for transfected receptors by using transfected markers to measure receptor/ligand interactions.
    Type: Grant
    Filed: October 20, 1997
    Date of Patent: June 15, 1999
    Assignee: Acadia Pharmaceuticals, Inc.
    Inventor: Mark Robert Brann
  • Patent number: 5885819
    Abstract: An enzyme exhibiting xylanase activity, which enzyme is immunologically reactive with an antibody raised against a purified xylanase derived from Aspergillus aculeatus, CBS 101.43. The enzyme may be used for degrading plant cell wall components e.g. in the preparation of feed, in baking, in the paper and pulp industry and in connection with separation of wheat into starch and gluten.
    Type: Grant
    Filed: July 30, 1997
    Date of Patent: March 23, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Lene Venke Kofod, Markus Sakari Kauppinen, Stephan Christgau, Hans Peter Heldt-Hansen, Henrik Dalb.o slashed.ge, Lene Nonboe Andersen, Joan Qi Si, Tina Sejersg.ang.rd Jacobsen, Niels Munk, Anette Mullertz
  • Patent number: 5885618
    Abstract: This invention relates to a directly compressible enzyme powder produced by mixing a liquid enzyme preparation with a suitable carrier, using the principle of wet granulation, whereby the step of freeze drying and spray-drying is avoided. The resulting enzyme powder has extraordinary good compression qualities and may directly be tabletted.
    Type: Grant
    Filed: November 28, 1995
    Date of Patent: March 23, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Inge Helmer Knap, Breian Knudsen
  • Patent number: 5886021
    Abstract: The present invention provides novel uses of compounds of general formula I ##STR1## wherein R.sup.1, R.sup.4 and R.sup.5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino)(lower alkoxy); and R.sup.2 and R.sup.3 are individually hydrogen or lower alkyl, or as a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier for the manufacture of a pharmaceutical composition for vasodilatory treatment or prophylaxis.
    Type: Grant
    Filed: August 18, 1997
    Date of Patent: March 23, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Niels Korsgaard, Michael Shalmi, Jan Ulrik Weis, Birgitte Hjort Guldhammer
  • Patent number: 5882718
    Abstract: A method for treating an aqueous protein solution so as to kill microorganisms which may be present therein, but without causing coagulation, comprises either (1) mixing the solution with sufficient enzymatically produced protein hydrolysate (H1) to prevent coagulation of the mixture when the mixture is subsequently subjected to a heat treatment to kill microorganisms, and then subjecting the mixture to such a heat treatment, or (2) using one or more enzymes to hydrolyze protein in the aqueous protein solution to an extent sufficient to prevent coagulation of the resulting liquid hydrolysate (H2) when it is subsequently subjected to a heat treatment to kill microorganisms, and then subjecting the liquid hydrolysate (H2) to such a heat treatment. The use of aqueous protein solutions treated in this manner in the production of a foodstuff, such as a meat-based foodstuff, contributes very significantly to reducing any risk of contamination of the foodstuff by harmful microorganisms.
    Type: Grant
    Filed: March 6, 1997
    Date of Patent: March 16, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Klaus Pommer, Egon Christensen
  • Patent number: 5866590
    Abstract: The present invention provides a new stable pharmaceutical composition containing tiagabine hydrochloride as active ingredient.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: February 2, 1999
    Assignee: Novo Nordisk A/S
    Inventors: J.o slashed.rgen Ryhl Svensson, Lars Nygaard, Tina Meinertz Andersen, Helle Weibel, Thyge Borup Hjorth
  • Patent number: 5863903
    Abstract: The present invention relates to hydroxy alkyl piperidine compounds and pharmaceutical compositions thereof which can be used to treat diabetes.
    Type: Grant
    Filed: March 14, 1995
    Date of Patent: January 26, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Karsten Lundgren, Ole Kirk
  • Patent number: 5859235
    Abstract: The invention relates to a novel substance with activity against insect pests of the order Diptera. The invention further relates to the substance which acts together with a Bacillus related pesticide, a chemical pesticide and/or a virus with pesticidal properties. The invention further relates to a novel strain(s) of Bacillus thuringiensis which produces such a substance. The invention further relates to pesticidal compositions comprising the substance and a pesticidal carrier, or the substance and a Bacillus related pesticide, a chemical pesticide and/or a virus with pesticidal properties as well as methods of using the pesticidal compositions to control a pest.
    Type: Grant
    Filed: July 11, 1994
    Date of Patent: January 12, 1999
    Assignee: Abbott Laboratories
    Inventors: Chi-Li Liu, William D. Lidster, Carmen Sanchez Lopez
  • Patent number: 5856164
    Abstract: An .alpha.-amylase characterized by having a specific activity at least 25% higher than the specific activity of Termamyl.RTM. at a temperature in the range of 25.degree. C. to 55.degree. C. and at a pH value in the range of pH 8 to pH 10.
    Type: Grant
    Filed: May 22, 1997
    Date of Patent: January 5, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Helle Outtrup, Henrik Bisg.ang.rd-Frantzen, Peter Rahbek stergaard, Michael Dolberg Rasmussen, Pia Van Der Zee